The Liberty Trial was an idea.
Cardiologists have been confused for years about revascularization in diabetics with multivessel infection. With the introduction of drug-eluting stents, these effects were looked at again, and the freedom trial (Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease) tried to put the question to rest. The freedom trial was a possible, randomized, multicenter superiority trial that compared multivessel PCI to CABG in diabetic patients who were already getting the best medical care. Three The National Heart, Lung, and Blood Institute paid for a trial that showed how drug-eluting stents could be used to move CABG to PCI. Outcomes that favor CABG have been driven by a drop in deaths from all causes and non-fatal myocardial infarction (MI), but this has been hampered by more strokes. The question seemed to be answered when the number of people who needed to be treated (NNT) for CABG was 12.6, while the number of people who needed t